A simple twist enhances Novo Nordisk's next-generation FlexPen
This article was originally published in Scrip
Executive Summary
Novo Nordiskhas announced a number of enhancements to its FlexPen prefilled insulin injection device, which includes a simple twist mechanism to attach and detach needles. This makes it the first pen device able to use a new generation of needles, the company says. Other changes include the need for less force to inject oneself, a single dose-setting mechanism, and a non-medical appearance. FlexPen is the most widely used prefilled insulin device in the world, the company notes.
You may also be interested in...
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.